News Headlines Article

After patient deaths, FDA warns about liver damage risk of hepatitis C medications
Washington Post

Federal regulators on Thursday warned that two hepatitis C medications from drug maker AbbVie can cause “serious liver injury” in patients with advanced forms of the disease.

The Food and Drug Administration said it had received numerous reports of patients who either died or had to undergo liver transplantation after receiving the treatments, known as Viekira Pak and Technivie. The agency said it had identified at least 26 such cases likely related to the drugs since late 2014, and that additional cases likely exist. The liver damage usually took place within four weeks of the start of treatment, and the patients involved already had cirrhosis of the liver, the agency said.